These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 31634190)

  • 21. Sequential Vacc-4x and romidepsin during combination antiretroviral therapy (cART): Immune responses to Vacc-4x regions on p24 and changes in HIV reservoirs.
    Tapia G; Højen JF; Ökvist M; Olesen R; Leth S; Nissen SK; VanBelzen DJ; O'Doherty U; Mørk A; Krogsgaard K; Søgaard OS; Østergaard L; Tolstrup M; Pantaleo G; Sommerfelt MA
    J Infect; 2017 Dec; 75(6):555-571. PubMed ID: 28917661
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of viral control in early HIV-1 infection is temporally associated with sequential escape from CD8+ T cell responses and decrease in HIV-1-specific CD4+ and CD8+ T cell frequencies.
    Oxenius A; Price DA; Trkola A; Edwards C; Gostick E; Zhang HT; Easterbrook PJ; Tun T; Johnson A; Waters A; Holmes EC; Phillips RE
    J Infect Dis; 2004 Aug; 190(4):713-21. PubMed ID: 15272399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression.
    Ruiz L; Martinez-Picado J; Romeu J; Paredes R; Zayat MK; Marfil S; Negredo E; Sirera G; Tural C; Clotet B
    AIDS; 2000 Mar; 14(4):397-403. PubMed ID: 10770542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kinetics of the T-cell receptor CD4 and CD8 V beta repertoire in HIV-1 vertically infected infants early treated with HAART.
    Romiti ML; Cancrini C; Castelli-Gattinara G; Di Cesare S; Ciaffi P; Bernardi S; De Gasperi MR; Halapi E; Rossi P
    AIDS; 2001 Nov; 15(16):2075-84. PubMed ID: 11684926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection.
    Plana M; García F; Gallart T; Tortajada C; Soriano A; Palou E; Maleno MJ; Barceló JJ; Vidal C; Cruceta A; Miró JM; Gatell JM
    AIDS; 2000 Sep; 14(13):1921-33. PubMed ID: 10997396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Defective IL-2 production by HIV-1-specific CD4 and CD8 T cells in an adolescent/young adult cohort.
    Kapogiannis BG; Henderson SL; Nigam P; Sharma S; Chennareddi L; Herndon JG; Robinson HL; Amara RR
    AIDS Res Hum Retroviruses; 2006 Mar; 22(3):272-82. PubMed ID: 16545014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. T-cell changes after a short-term exposure to maraviroc in HIV-infected patients are related to antiviral activity.
    Pulido I; Machmach K; Romero-Sánchez MC; Genebat M; Mendez-Lagares G; Ruiz-Mateos E; Leal M
    J Infect; 2012 Apr; 64(4):417-23. PubMed ID: 22227467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Novel Immunogen Selectively Eliciting CD8
    Ishii H; Terahara K; Nomura T; Takeda A; Okazaki M; Yamamoto H; Tokusumi T; Shu T; Matano T
    J Virol; 2020 Mar; 94(8):. PubMed ID: 32024773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery.
    Massanella M; Negredo E; Puig J; Puertas MC; Buzón MJ; Pérez-Álvarez N; Carrillo J; Clotet B; Martínez-Picado J; Blanco J
    AIDS; 2012 Nov; 26(18):2285-93. PubMed ID: 23018435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In-vitro viral suppressive capacity correlates with immune checkpoint marker expression on peripheral CD8+ T cells in treated HIV-positive patients.
    Pannus P; Adams P; Willems E; Heyndrickx L; Florence E; Rutsaert S; De Spiegelaere W; Vandekerckhove L; Seguin-Devaux C; Vanham G
    AIDS; 2019 Mar; 33(3):387-398. PubMed ID: 30702513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Effect of Latency Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication.
    Walker-Sperling VE; Pohlmeyer CW; Tarwater PM; Blankson JN
    EBioMedicine; 2016 Jun; 8():217-229. PubMed ID: 27428432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV replication leads to skewed maturation of CD8-positive T-cell responses in infected children.
    Montesano C; Anselmi A; Palma P; Bernardi S; Cicconi R; Mattei M; Castelli-Gattinara G; Ciccozzi M; Colizzi V; Amicosante M
    New Microbiol; 2010 Oct; 33(4):303-9. PubMed ID: 21213588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV.
    Negredo E; Jiménez M; Puig J; Loste C; Pérez-Álvarez N; Urrea V; Echeverría P; Bonjoch A; Clotet B; Blanco J
    PLoS One; 2020; 15(9):e0238575. PubMed ID: 32941476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunological and virological effects of structured treatment interruptions following exposure to hydroxyurea plus didanosine.
    Benito JM; López M; Ballesteros C; Lozano S; Capa L; Barreiro P; Sempere J; Gonzalez-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2006 Aug; 22(8):734-43. PubMed ID: 16910828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma HIV load and proviral DNA decreases after two standard antiretroviral regimens in HIV-positive patients naïve to antiretrovirals.
    Torti C; Quiros-Roldan ME; Cologni G; Nichelatti M; Ceresoli F; Pinti M; Nasi M; Cossarizza A; Lapadula G; Costarelli S; Manca N; Gargiulo F; Magoni M; Carosi G
    Curr HIV Res; 2008 Jan; 6(1):43-8. PubMed ID: 18288974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
    Cillo AR; Hilldorfer BB; Lalama CM; McKinnon JE; Coombs RW; Tenorio AR; Fox L; Gandhi RT; Ribaudo H; Currier JS; Gulick RM; Wilkin TJ; Mellors JW
    AIDS; 2015 Oct; 29(16):2121-9. PubMed ID: 26544577
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pilot study to assess inflammatory biomarker changes when raltegravir is added to a virologically suppressive HAART regimen in HIV-1-infected patients with limited immunological responses.
    Lichtenstein KA; Armon C; Nagabhushanam V; Efaw BJ; Frazer-Abel A; Hiserote ME; Alam R
    Antivir Ther; 2012; 17(7):1301-9. PubMed ID: 22948290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.
    Oxenius A; Price DA; Günthard HF; Dawson SJ; Fagard C; Perrin L; Fischer M; Weber R; Plana M; García F; Hirschel B; McLean A; Phillips RE
    Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13747-52. PubMed ID: 12370434
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes.
    Oxenius A; Price DA; Easterbrook PJ; O'Callaghan CA; Kelleher AD; Whelan JA; Sontag G; Sewell AK; Phillips RE
    Proc Natl Acad Sci U S A; 2000 Mar; 97(7):3382-7. PubMed ID: 10737796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Low Frequency of IL-17-Producing CD8
    Perdomo-Celis F; Feria MG; Taborda NA; Rugeles MT
    Front Immunol; 2018; 9():2502. PubMed ID: 30420859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.